Saad Atiq, MD

Dr. Malone has a strong interest in medical education and leadership. She directs both the Hematology and Medical Oncology and Stem Cell Transplant and Cellular Therapy fellowships, and is Senior Associate Dean for Graduate Medical Education (GME), the largest GME program in the United States. In her career, Dr. Malone has served as an educator and mentor for medical students, residents, and fellows. She demonstrates a long-standing commitment as educator for undergraduate medical students in the second-year hematology course, as an advisor for residents, and as a member of the Clinical Competency Committee. In her role as fellowship director, Dr. Malone led the merger of The Mount Sinai Hospital and Mount Sinai Beth Israel Hematology and Medical Oncology fellowship programs, creating the first Mount Sinai Health System-wide fellowship.

Dr. Sundar Jagannath is Director of the Center of Excellence for Multiple Myeloma and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — a relatively rare cancer of the bone marrow. Prior to joining Mount Sinai, Dr. Jagannath served as chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed in April 2010. The transplant program, with stored stem cells of more than 300 patients, and the myeloma program with ongoing clinical trials, have been integrated into The Tisch Cancer Institute.

Krzysztof Misiukiewicz, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. A member of the faculty since 2009, Dr. Misiukiewicz has clinical expertise in the medical management of head and neck and thyroid cancers. He is Clinical Director of Research in Head and Neck, Clinical Director of the Center for Personalized Cancer Therapeutics (CPCT) at The Tisch Cancer Institute, and Chairman of the Oncology Pharmacy & Therapeutics Committee. Dr. Misiukiewicz is Principal Investigator of the key personalized clinical trials offered at CPCT; he holds a Master’s degree in clinical research. Dr. Misiukiewicz investigates new ways to combine traditional treatments, such as chemotherapy and radiotherapy, with the latest targeted agents and immunotherapy in order to improve treatment results and decrease side effects in patients with head and neck and thyroid cancers. He is also working on identifying drugs that target the genetic changes of an individual’s tumor with an understanding of tumor genetic complexity. Using a personalized medicine approach, Dr. Misiukiewicz offers patients a customized care plan tailored to their specific cancer and access to innovative treatments.